Business
-
A month after regaining rights to PUR1800 and other inhaled narrow spectrum kinase inhibitors from Johnson & Johnson, Pulmatrix has announced that it may also reacquire the rights to its Pulmazole intraconazole DPI (PUR 1900).… Read more . . .
-
Inhalation CDMO Vectura has signed an agreement with Inspira Pharmaceuticals to develop an inhaled formulation of a plant extract Inspira is developing for the treatment of COVID-19, the company said. Vectura will create a version of… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of Ryaltris-AZ mometasone furoate / azelastine nasal spray for the treatment of allergic rhinitis in India, touting the low cost of the nasal spray compared to similar products. According to… Read more . . .
-
Hikma Pharmaceuticals said that the FDA has approved an amendment to the company’s ANDA for its generic version of Advair Diskus fluticasone propionate / salmeterol DPI, and the company has subsequently restarted the launch of… Read more . . .
-
NeuroRx and Relief Therapeutics have each issued press releases enumerating disagreements between the companies regarding development of Zyesami aviptadil (RLF-100), a synthetic vasoactive intestinal peptide. The two companies are partnered on development of the formulation… Read more . . .
-
Virpax Pharmaceuticals announced that a study of its MMS019 powder “masking spray” in mice demonstrated “a marked inhibition of viral replication in the mouse nasal passages” for mice infected with SARS-CoV-2 and then given MMS019 intranasally… Read more . . .
-
GH Research Ireland has closed a $125 million Series B financing round to fund development of its GH001 inhaled 5-MeO-DMT, the company announced. 5-MeO-DMT is psychedelic found in the venom of certain toads. GH is currently developing… Read more . . .
-
Johnson & Johnson has decided not to exercise an option acquired in a 2020 agreement with Pulmatrix for development and commercialization of Pulmatrix’s portfolio of inhaled narrow spectrum kinase inhibitors (NSKIs), including PUR1800. J&J’s Lung… Read more . . .
-
AIM ImmunoTech has announced that it will definitely advance an intranasal formulation of its Ampligen rintatolimod into a Phase 2 trial after the initial dose tested in a Phase 1 study showed no safety problems.… Read more . . .
-
Seelos Therapeutics has signed a strategic device partnership agreement with Aptar Pharma for the use of Aptar’s Bidose Liquid System (BDS) for Seelos’ SLS-002 intranasal ketamine, Seelos said. SLS-002 is in Phase 2 development for the… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here


